Literature DB >> 12377725

Sepiapterin treatment in atherosclerosis.

Margaret M Tarpey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377725     DOI: 10.1161/01.atv.0000038144.37823.bf

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  6 in total

Review 1.  Novel strategies to ameliorate radiation injury: a possible role for tetrahydrobiopterin.

Authors:  Maaike Berbée; Qiang Fu; K Sree Kumar; Martin Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats.

Authors:  Prasad V G Katakam; James A Snipes; Mesia M Steed; David W Busija
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-11       Impact factor: 6.200

3.  Tetrahydrobiopterin improves endothelial dysfunction and vascular oxidative stress in microvessels of intrauterine undernourished rats.

Authors:  Maria do Carmo P Franco; Zuleica B Fortes; Eliana H Akamine; Elisa M Kawamoto; Cristoforo Scavone; Luiz Roberto Giorgetti de Britto; Marcelo N Muscara; Simone A Teixeira; Rita C A Tostes; Maria Helena C Carvalho; Dorothy Nigro
Journal:  J Physiol       Date:  2004-05-07       Impact factor: 5.182

4.  Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability.

Authors:  Ling Gao; Yuh-Fen Pung; Jun Zhang; Peng Chen; Ting Wang; Min Li; Miguel Meza; Ligia Toro; Hua Cai
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

5.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression.

Authors:  Nicholas J Alp; Shafi Mussa; Jeffrey Khoo; Shijie Cai; Tomasz Guzik; Andrew Jefferson; Nicky Goh; Kirk A Rockett; Keith M Channon
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 6.  Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease.

Authors:  Hajime Otani
Journal:  Oxid Med Cell Longev       Date:  2013-04-30       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.